Decreased expression of RIPK3 was connected with poor prognosis for women with breast cancer [55], and decreased OS and PFS in patients with colorectal cancer [46], as well as accelerated leukogenesis in patients with AML [56,57]. Here, RIPK3 is linked to acute myeloid leukemia.